Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice

Journal of Bone and Mineral Research

Volumn 18, Issue 2, 2003, Pages 270-277

  Cao, Jay ^a,b   Venton, Laura ^a,b   Sakata, Takeshi ^a,b   Halloran, Bernard P ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Bone; Osteoblasts; Osteoprotegerin; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

AGING; ANIMAL CELL; ARTICLE; ARTICULAR CARTILAGE; BONE MASS; CANCELLOUS BONE; CELL MATURATION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; STEM CELL; STROMA CELL;

NON-PROGRAMMATIC;

AGING; ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; BONE AND BONES; CARRIER PROTEINS; CELLS, CULTURED; GLYCOPROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 0037302038     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.2.270     Document Type: Article

References (26)

1. Kleerekoper M, Avioli L 1998 Osteoporosis Pathogenesis and Therapy, In: Avioli L, Crane SM (eds.) Metabolic Bone Disease, Academic Press, San Diego, CA, USA, pp. 387-409.
2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
3. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for Osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
5. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337.
6. Burgess T, Qian Y, Kaufman S, Ring B, Van G, Capparelli C, Kelly M, Hsu H, Boyle W, Dunstan CR, Hu S, Lacey DL 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538.
7. Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G, Truneh A 1997 Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204:35-46.
8. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323.
9. Mizuno A, Amizuka S, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H 1998 Severe osteoporosis in mice lacking osteoclastogenesis factor/OPG. Biochem Biophys Res Commun 247:610-615.
10. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS 1998 Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Gene Dev 12:1260-1268.
11. Fazzalari NL, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM 2001 The ratio of messenger RNA levels of activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res 16:1015-1027.
12. Makhluf HA, Mueller SM, Mizuno S, Glowacki J 2000 Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three dimensional collagen sponges. Biochem Biophys Res Commun 268:669-672.
13. Browner WS, Lui LY, Cummings SR 2001 Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J Clin Endocrinol Metab 86:631-637.
14. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y 1999 Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518-527.
15. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD 2001 Osteoprotegerin serum levels in men: Correlation with age, estrogen and testosterone status. J Clin Endocrinol Metab 86:3162-3165.
16. Ikeda T, Utsuyama M, Hirokawa K 2001 Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res 16:1416-1425.
17. Perkins SL, Gibbons R, Kling S, Kahn AJ 1994 Age-related bone loss in mice is associated with an increased osteoclast progenitor pool. Bone 15:65-72.
18. Bikle D, Majumdar S, Laib A, Powell-Braxton L, Rosen C, Beamer W, Nauman E, Leary C, Halloran B 2001 The skeletal structure of insulin-like growth factor-I deficient mice. J Bone Miner Res 16:2320-2329.
19. Kostenuik PJ, Harris J, Halloran BP, Turner RT, Morey-Holton ER, Bikle DD 1999 Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and insulin-like growth factor-I. J Bone Miner Res 14:21-31.
20. Nauman EA, Satcher RL, Keaveny TM, Halloran BP, Bikle DD 2001 Osteoblasts respond to pulsatile fluid flow with short-term increases in PGE(2) but no change in mineralization. J Appl Physiol 90:1849-1854.
21. Bar-Shira-Maymon B, Coleman R, Cohen A, Steinhagen-Thiessen E, Silbermann M 1989 Age related bone loss in lumbar vertebrae of CW-1 female mice: A histomorphometric study. Calcif Tissue Int 44:36-45.
22. Kostenuik PJ, Shalboub V 2001 Osteoprotegerin: A physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613-635.
23. Lee SK, Lorenzo JA 1999 Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 140:3552-3261.
24. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno G, Churgay L, Chandrasekhar S, Martin TJ 2000 In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15:863-871.
25. Halloran B, Ferguson V, Simske S, Burghardt A, Venton L, Majumdar S 2002 Changes in bone structure and mass with advancing age in the male C57BL/6 mouse. J Bone Miner Res 17:1044-1050.
26. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL 2000 The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast linage cells is developmentally regulated. Endocrinology 141:4768-4776.